Related Experiment Videos
Absence of structural alterations of the multidrug resistance genes in transitional cell carcinoma
1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.
Abstract:
Tumor DNA from 27 patients with treated or untreated transitional cell carcinomas of the urinary tract was screened for genomic alterations of the multidrug resistance genes in order to determine whether structural changes of these genes are important in primary urothelial tumors. None of the tumors showed evidence of amplification or rearrangements of either mdr1 or mdr2. The lack of amplification or rearrangements observed in these tumors suggests that structural alterations of the mdr1 and mdr2 genes are not important mediators of drug resistance in TCC.
Insights
Genomic alterations in multidrug resistance genes (mdr1 and mdr2) were not found in transitional cell carcinomas. This suggests these structural changes do not significantly contribute to drug resistance in primary urothelial tumors.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Transitional cell carcinoma (TCC) is a significant malignancy of the urinary tract.
- Multidrug resistance (MDR) is a major challenge in TCC treatment.
- The role of specific gene alterations in primary TCC drug resistance requires further investigation.
Purpose of the Study:
- To investigate the presence of genomic alterations in multidrug resistance genes (mdr1 and mdr2) in primary urothelial tumors.
- To determine if structural changes in mdr1 and mdr2 are associated with drug resistance in transitional cell carcinomas.
Main Methods:
- Tumor DNA was extracted from 27 patients with transitional cell carcinomas.
- Screening for genomic alterations, including amplification and rearrangements, of mdr1 and mdr2 genes was performed.
Main Results:
- No evidence of amplification was detected in either the mdr1 or mdr2 genes.
- No rearrangements were observed in the mdr1 or mdr2 genes across the studied tumor samples.
Conclusions:
- Structural alterations of the mdr1 and mdr2 genes are not a significant factor in primary urothelial TCC.
- The findings suggest that other mechanisms may be responsible for drug resistance in these tumors.